Clinical Trials Directory

Trials / Completed

CompletedNCT00004157

Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors

Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
Sponsor
Fred Hutchinson Cancer Center · Academic / Other
Sex
All
Age
70 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side effects after transplant. PURPOSE: Phase II trial to study the effectiveness of interleukin-11 plus filgrastim prior to peripheral stem cell transplantation in patients who have non-Hodgkin's lymphoma, Hodgkin's disease, breast cancer, or other solid tumors.

Detailed description

OBJECTIVES: I. Determine the tolerability of interleukin-11 (IL-11) with filgrastim (G-CSF) in patients with non-Hodgkin's lymphoma, Hodgkin's disease, breast cancer, or other solid tumors. II. Evaluate the ability to collect CD34 cells and the number of apheresis collections required to reach the target number of CD34 cells in this patient population. III. Evaluate the time to recovery of platelets and neutrophils and the number of platelet and red blood cell transfusions required following IL-11 and G-CSF mobilized peripheral blood stem cell infusion in these patients. OUTLINE: Patients receive interleukin-11 (IL-11) subcutaneously (SQ) on days 1-10 and filgrastim (G-CSF) SQ on days 4-10. Patients undergo peripheral blood stem cell (PBSC) collection on days 7-10 until the target number of cells is achieved or for a maximum of 4 collections. Patients are followed until transplantation. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2 years.

Conditions

Interventions

TypeNameDescription
BIOLOGICALfilgrastim
BIOLOGICALrecombinant interleukin-11

Timeline

Start date
2000-08-01
Primary completion
2002-04-01
Completion
2002-04-01
First posted
2004-02-12
Last updated
2010-04-02

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00004157. Inclusion in this directory is not an endorsement.